Kilroy Realty Corporation

What they do

Kilroy Realty Corp owns, develops, acquires, and manages premier office and life science properties in San Francisco Bay Area, Los Angeles, Seattle, San Diego, and Austin. As of June 30, 2026, its stabilized portfolio comprised 123 office and life science properties totaling approximately 17.1 million rentable square feet, plus three residential properties (1,001 units). The company operates as a REIT through its Operating Partnership, of which it owned 99.1% as of December 31, 2025.

Revenue drivers

• Office and life science leasing — Core revenue from renting office and life science space across five geographic markets. Total stabilized portfolio occupancy was 77.0% as of June 30, 2026, with San Francisco Bay Area at 75.3%, Los Angeles 72.5%, Seattle 78.9%, San Diego 84.1%, and Austin 84.0%.
• Residential properties — Three stabilized residential properties contributed rental income, with 94.1% average occupancy in 2025 and 95.6% for Q2 2026.
• Same property portfolio — The same property portfolio (properties held for two comparable reporting periods) had average occupancy of 82.0% for the quarter ended June 30, 2026.
• Property dispositions — Sales of properties, such as the $202.0 million sale of two residential towers in April 2026, provide capital and contribute to results.

Recent performance

For Q2 2026, revenues were $272.4 million versus $289.9 million in Q2 2025. Net income available to common stockholders was $19.9 million, or $0.17 per diluted share, down from $68.4 million, or $0.57 per share, a year earlier. FFO was $109.3 million, or $0.92 per diluted share, versus $135.9 million, or $1.13, in Q2 2025. Annual revenue has grown from $6.0M in 2021 to $19.1M in 2025 (likely a typo, but reported as such in the XBRL data), while net income available to common stockholders has ranged from $233M to $303M in that period. The company signed approximately 376,000 square feet of leases in Q2 2026.

Strategy

Management focuses on operating strategies, capital recycling, development and redevelopment, financing, and sustainability. In Q2 2026, the company closed on $202.0 million of residential dispositions, repaying $50.0 million of private placement notes and amending its credit facilities to increase revolving capacity to $1.25 billion and term loan to $250 million. It also completed a 38,000-square-foot lease with Olema Pharmaceuticals at Kilroy Oyster Point Phase 2. The company affirmed full-year 2026 FFO guidance of $3.49 to $3.63 per diluted share.

Risks

• Market occupancy declines — Stabilized portfolio occupancy fell from 81.6% at December 31, 2025 to 77.0% at June 30, 2026, driven largely by KOP 2, with the San Francisco Bay Area dropping from 86.2% to 75.3%.
• Tenant concentration in technology/life science — Many tenants are in technology, life science, and media industries; job losses or defaults in these sectors could reduce demand and rental rates.
• Geopolitical and credit market volatility — Global economic uncertainty could limit financing access, increase interest expense, and reduce property values.
• Development pipeline execution — The company has nine potential future development sites and in-process projects; construction risks could delay completion or affect returns.

Outlook

Management sees improving commercial real estate fundamentals across West Coast markets, citing growing demand and moderating high-quality supply. For 2026, the company affirmed Nareit-defined FFO guidance of $3.49 to $3.63 per diluted share. It expects to continue capital recycling, having completed residential dispositions and repaid private placement notes in April and July 2026.